Dr. Zhao is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
515 Minor Ave FL 1
Seattle, WA 98104Phone+1 206-386-9500Fax+1 206-386-9605
Education & Training
University of WashingtonFellowship, Hematology and Medical Oncology, 2010 - 2013
Zucker School of Medicine at Hofstra/NorthwellResidency, Internal Medicine, 2007 - 2010
Memorial Sloan Kettering Cancer CenterFellowship, Research, 2003 - 2006
University of Texas Health Sciences CenterPhD, Molecular Medicne, 1997 - 2002
Peking Union Medical CollegeClass of 1996
Certifications & Licensure
WA State Medical License 2010 - 2025- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer Start of enrollment: 2015 Apr 29
- An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With SoC, Versus SoC Alone, in Adult Male Patients With mHSPC Start of enrollment: 2021 Jun 09
- Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment Start of enrollment: 2021 Feb 25
- Join now to see all
Publications & Presentations
PubMed
- 31 citationsBelzutifan plus cabozantinib for patients with advanced clear cell renal cell carcinoma previously treated with immunotherapy: an open-label, single-arm, phase 2 study.Toni K Choueiri, David F McDermott, Jaime Merchan, Todd M Bauer, Robert Figlin
The Lancet. Oncology. 2023-05-01 - 6 citationsIncorporating radioligand therapy in clinical practice in the United States for patients with prostate cancer.Jeremie Calais, Stephen M Eulau, Linda Gardner, Ralph J Hauke, Ayse T Kendi
Cancer Treatment Reviews. 2023-04-01 - 38 citationsDNA damage induces GDNF secretion in the tumor microenvironment with paracrine effects promoting prostate cancer treatment resistance.Roland M. Huber, Jared M. Lucas, Luis A. Gomez-Sarosi, Ilsa Coleman, Song Zhao
Oncotarget. 2015-01-08
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
